


Status: Currently Official on 15-Feb-2025
Official Date: Official as of 01-Aug-2024
Document Type: USP Monographs
DocId: GUID-2C608858-CE84-44F4-A2E1-33682A5F6B03_6_en-US
DOI: https://doi.org/10.31003/USPNF_M55780_06_01
DOI Ref: zipti

© 2025 USPC
Do not distribute

Naproxen Sodium

Change to read:

▲



▲ (USP 1-Aug-2024)

$C_{14}H_{13}NaO_3$ 252.24

2-Naphthaleneacetic acid, 6-methoxy- α -methyl-, sodium salt, (S)-;

(-)-Sodium (S)-6-methoxy- α -methyl-2-naphthaleneacetate;

▲Sodium (S)-2-(6-Methoxynaphthalen-2-yl)propanoate▲ (USP 1-Aug-2024) CAS RN[®]: 26159-34-2; UNII: 9TN87S3A3C.

DEFINITION

Naproxen Sodium contains NLT 98.0% and NMT 102.0% of naproxen sodium ($C_{14}H_{13}NaO_3$), calculated on the dried basis.

IDENTIFICATION

Change to read:

- A. [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy](#): 197K ▲ or 197A ▲ (USP 1-Aug-2024)

Change to read:

- B. ▲The retention time of the major peak of the *Sample solution* corresponds to that of the naproxen peak in the *System suitability solution*, as obtained in the [Enantiomeric Purity Test](#).▲ (USP 1-Aug-2024)

ASSAY

Change to read:

PROCEDURE

▲**Solution A:** 0.1% [glacial acetic acid](#) in [water](#)

Solution B: 0.01% [glacial acetic acid](#) in [methanol](#)

Mobile phase: See [Table 1](#). The recommended equilibration time after the gradient is 5–10 min.

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	45	55
20	45	55
27	20	80
32	20	80
32.1	45	55
35	45	55

Diluent: [Methanol](#) and [water](#) (50:50)

Standard solution: 110 µg/mL of [USP Naproxen Sodium RS](#) in *Diluent*

Sample solution: 110 µg/mL of Naproxen Sodium in *Diluent*

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC**Detector:** UV 272 nm**Column:** 4.6-mm × 15-cm; 3.5-μm packing [L1](#)**Column temperature:** 35°**Flow rate:** 1 mL/min**Injection volume:** 20 μL**System suitability****Sample:** *Standard solution***Suitability requirements****Tailing factor:** NMT 2.0**Relative standard deviation:** NMT 0.73%**Analysis****Samples:** *Standard solution* and *Sample solution*Calculate the percentage of naproxen sodium ($C_{14}H_{13}NaO_3$) in the portion of Naproxen Sodium taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response of naproxen from the *Sample solution* r_S = peak response of naproxen from the *Standard solution* C_S = concentration of [USP Naproxen Sodium RS](#) in the *Standard solution* (μg/mL) C_U = concentration of Naproxen Sodium in the *Sample solution* (μg/mL) ▲ (USP 1-Aug-2024)**Acceptance criteria:** 98.0%–102.0% on the dried basis**IMPURITIES****Change to read:**• **ORGANIC IMPURITIES**▲ **Solution A, Solution B, Mobile phase, and Diluent:** Prepare as directed in the Assay.**System suitability solution:** 110 μg/mL of [USP Naproxen Sodium RS](#) and 0.5 μg/mL each of [USP Naproxen Related Compound K RS](#), [USP Naproxen Related Compound A RS](#), and [USP Naproxen Related Compound L RS](#) in *Diluent***Standard solution:** 0.1 μg/mL each of [USP Naproxen Sodium RS](#), [USP Naproxen Related Compound E RS](#), [USP Naproxen Related Compound A RS](#), and [USP Naproxen Related Compound L RS](#) in *Diluent***Sensitivity solution:** 0.05 μg/mL each of [USP Naproxen Sodium RS](#), [USP Naproxen Related Compound A RS](#), [USP Naproxen Related Compound L RS](#), and [USP Naproxen Related Compound E RS](#) in *Diluent* from *Standard solution***Sample solution:** 110 μg/mL of Naproxen Sodium in *Diluent***Chromatographic system**(See [Chromatography \(621\)](#), [System Suitability](#).)**Mode:** LC**Detector:** UV 240 nm**Column:** 4.6-mm × 15-cm; 3.5-μm packing [L1](#)**Column temperature:** 35°**Flow rate:** 1 mL/min**Injection volume:** 20 μL**System suitability****Samples:** *System suitability solution*, *Standard solution*, and *Sensitivity solution*[NOTE—See [Table 2](#) for the relative retention times.]**Suitability requirements****Resolution:** NLT 1.5 between naproxen related compound K and naproxen related compound A; NLT 2.0 between naproxen related compound L and naproxen, *System suitability solution***Relative standard deviation:** NMT 5.0% for each peak, *Standard solution***Signal-to-noise ratio:** NLT 10 for each peak, *Sensitivity solution***Analysis****Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of naproxen related compound E, naproxen related compound A, and naproxen related compound L in the portion of Naproxen Sodium taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response of naproxen related compound E, naproxen related compound A, or naproxen related compound L from the *Sample solution*

r_s = peak response of naproxen related compound E, naproxen related compound A, or naproxen related compound L from the *Standard solution*

C_s = concentration of [USP Naproxen Related Compound E RS](#), [USP Naproxen Related Compound A RS](#), or [USP Naproxen Related Compound L RS](#) in the *Standard solution* (µg/mL)

C_U = concentration of Naproxen Sodium in the *Sample solution* (µg/mL)

Calculate the percentage of naproxen related compound K and any unspecified impurity in the portion of Naproxen Sodium taken:

$$\text{Result} = (r_U/r_s) \times (C_s/C_U) \times (1/F) \times 100$$

r_U = peak response of naproxen related compound K or any unspecified impurity from the *Sample solution*

r_s = peak response of naproxen from the *Standard solution*

C_s = concentration of [USP Naproxen Sodium RS](#) in the *Standard solution* (µg/mL)

C_U = concentration of Naproxen Sodium in the *Sample solution* (µg/mL)

F = relative response factor, 0.71 for naproxen related compound K and 1.0 for unspecified impurity

Acceptance criteria: See [Table 2](#). The reporting threshold is 0.05%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Naproxen related compound K, if present	0.66	0.10
Naproxen related compound A	0.71	0.06
Naproxen related compound L	0.88	0.1
Naproxen	1.0	—
Naproxen related compound E	1.63	0.1
Any unspecified impurity	—	0.10
Total impurities	—	0.5▲ (USP 1-Aug-2024)

Change to read:

- ▲ **LIMIT OF ▲** (USP 1-Aug-2024) **FREE NAPROXEN**

Sample: 5.0 g

Analysis: Transfer the *Sample* to a separator and add 25 mL of [water](#). Extract the solution with three 15-mL portions of [chloroform](#). Evaporate the combined extracts on a steam bath to dryness. Dissolve the residue in 10 mL of a mixture of [methanol](#) and [water](#) (3:1), previously neutralized with 0.1 N sodium hydroxide to the phenolphthalein endpoint. Add phenolphthalein TS, and titrate with 0.10 N sodium hydroxide.

Acceptance criteria: NMT 2.2 mL is consumed (1.0%)

Add the following:

▲ **ENANTIOMERIC PURITY TEST**

[NOTE—Protect solutions containing naproxen from light.]

Mobile phase: [Hexane](#), [isopropanol](#), [acetonitrile](#), and [glacial acetic acid](#) (84.5: 10: 5: 0.5)

System suitability solution: 25 µg/mL each of [USP Naproxen Sodium RS](#) and [USP Naproxen Related Compound G RS](#) in *Mobile phase*

Standard solution: 1.25 µg/mL of [USP Naproxen Related Compound G RS](#) in *Mobile phase*

Sample stock solution: Equivalent to 500 µg/mL of Naproxen in [tetrahydrofuran](#) prepared as follows. Dissolve 25 mg of naproxen sodium in 15 mL of [water](#) and add 1 mL of [hydrochloric acid](#). Add 10 mL of [ethyl acetate](#) and shake well to extract the free naproxen. Separate the [ethyl acetate](#) layer and repeat the extraction with an additional 10 mL of [ethyl acetate](#). Combine the two [ethyl acetate](#) extractions and evaporate to dryness under vacuum. Dissolve the residue in 50 mL of [tetrahydrofuran](#).

Sample solution: Equivalent to 50 µg/mL of Naproxen in *Mobile phase* from *Sample stock solution*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 263 nm**Column:** 4.6-mm × 25-cm; 5-μm packing [L102](#)**Flow rate:** 2 mL/min**Injection volume:** 20 μL**Run time:** NLT 1.5 times the retention time of the naproxen peak**System suitability****Samples:** *System suitability solution* and *Standard solution*

[NOTE—The relative retention times for naproxen related compound G and naproxen are approximately 0.7 and 1.0, respectively.]

Suitability requirements**Resolution:** NLT 3.0 between naproxen related compound G and naproxen, *System suitability solution***Relative standard deviation:** NMT 2.0%, *Standard solution***Analysis****Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of naproxen related compound G in the portion of Naproxen Sodium taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response of naproxen related compound G from the *Sample solution* r_S = peak response of naproxen related compound G from the *Standard solution* C_S = concentration of [USP Naproxen Related Compound G RS](#) in the *Standard solution* (μg/mL) C_U = concentration of Naproxen Sodium in the *Sample solution* (μg/mL)**Acceptance criteria:** NMT 2.5%▲ (USP 1-Aug-2024)**SPECIFIC TESTS****Delete the following:**▲• [OPTICAL ROTATION \(781S\), Procedures, Specific Rotation](#)▲ (USP 1-Aug-2024)**Change to read:**• [LOSS ON DRYING \(731\)](#)**Analysis:** ▲Dry in vacuum at 105° for 3 h.▲ (ERR 1-Aug-2024)**Acceptance criteria:** NMT 1.0%**ADDITIONAL REQUIREMENTS**• **PACKAGING AND STORAGE:** Preserve in tight containers.**Change to read:**• [USP REFERENCE STANDARDS \(11\)](#)[USP Naproxen Sodium RS](#)▲ [USP Naproxen Related Compound A RS](#)

6-Methoxy-2-naphthoic acid.

 $C_{12}H_{10}O_3$ 202.21[USP Naproxen Related Compound E RS](#)

(S)-Methyl 2-(6-methoxynaphthalen-2-yl)propanoate.

 $C_{15}H_{16}O_3$ 244.29[USP Naproxen Related Compound G RS](#)

(R)-2-(6-Methoxynaphthalen-2-yl)propanoic acid.

 $C_{14}H_{14}O_3$ 230.26[USP Naproxen Related Compound K RS](#)

1-(6-Methoxynaphthalen-2-yl)ethanol.

 $C_{13}H_{14}O_2$ 202.25[USP Naproxen Related Compound L RS](#)

1-(6-Methoxynaphthalen-2-yl)ethanone.

 $C_{13}H_{12}O_2$ 200.24▲ (USP 1-Aug-2024)**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
NAPROXEN SODIUM	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 47(4)

Current DocID: GUID-2C608858-CE84-44F4-A2E1-33682A5F6B03_6_en-US

DOI: https://doi.org/10.31003/USPNF_M55780_06_01

DOI ref: [zipti](#)

OFFICIAL